Related Experiment Video
Updated: Jul 13, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Association of transforming growth factor-beta1 gene polymorphism with familial vesicoureteral reflux
Seika Kuroda1, Valeria Solari, Prem Puri
1Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland.
Purpose:
Familial clustering of vesicoureteral reflux suggests that genetic factors have an important role in the pathogenesis of vesicoureteral reflux. Transforming growth factor-beta1 is a multifunctional peptide that controls proliferation and differentiation in many cell types. Recently an association between the transforming growth factor-beta1 -509 and +869 gene polymorphism, and renal parenchymal scarring was reported. We investigated the genetic contribution of transforming growth factor-beta1 in familial vesicoureteral reflux by examining the genotype frequencies of transforming growth factor-beta1 polymorphic variants.
Materials And Methods:
The study included 141 families in which 1 or more siblings had primary vesicoureteral reflux. Renal parenchymal scarring was assessed using dimercapto-succinic acid scans. Genotyping was performed in 280 patients with vesicoureteral reflux, including 133 index patients and 147 siblings, and in 74 controls for the position -509 and the coding region at position 10 (+869) of the transforming growth factor-beta1 gene polymorphism by polymerase chain reaction, gel analysis and appropriate restriction digest.
Results:
The genotype frequency of -509CC was significantly increased in the familial vesicoureteral reflux group compared to controls (58% vs 33%, p <0.01), whereas -509TT genotype frequency was significantly lower in the familial vesicoureteral reflux group compared to controls (7.5% vs 28%, p <0.01). Similarly there was a significant increase in the +869TT genotype (52% vs 32%, p <0.05), while the +869CC genotype was significantly lower in patients with familial vesicoureteral reflux compared to controls (11% vs 24%, p <0.01). There were no significant differences in transforming growth factor-beta1 genotype distribution between patients with vesicoureteral reflux with and without renal parenchymal scarring.
Conclusions:
To our knowledge this study demonstrates for the first time the association of the cytokine transforming growth factor-beta1 gene polymorphism in patients with familial vesicoureteral reflux. Individuals with the transforming growth factor-beta1 -509CC and 869TT genotype may have increased susceptibility to vesicoureteral reflux.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
TGF - β Signaling Pathway
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Regulation of Angiogenesis and Blood Supply
Gastroesophageal Reflux Disease
